Citation Impact
Citing Papers
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
2008 Standout
Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women
2010 StandoutScience
Nucleic acid detection with CRISPR-Cas13a/C2c2
2017 StandoutScience
CD4+ Count–Guided Interruption of Antiretroviral Treatment
2006 Standout
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype
2007 StandoutNobel
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response
2009 StandoutNobel
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
No health without mental health
2007 Standout
A view on drug resistance in cancer
2019 StandoutNature
Expanded Access to Highly Active Antiretroviral Therapy: A Potentially Powerful Strategy to Curb the Growth of the HIV Epidemic
2008
A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter
1996
Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults
2009
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
2007
Rethinking amide bond synthesis
2011 StandoutNature
Dicer-TRBP Complex Formation Ensures Accurate Mammalian MicroRNA Biogenesis
2014 StandoutNobel
Factors Associated with the Emergence of K65R in Patients with HIV‐1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir
2008
The Outcome of Hepatitis C Virus Infection Is Predicted by Escape Mutations in Epitopes Targeted by Cytotoxic T Lymphocytes
2001 StandoutNobel
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort
2009
The Survival Benefits of AIDS Treatment in the United States
2006
Cushing's syndrome
2015 Standout
Development of Cervical Fat Pads Following Therapy with Human Immunodeficiency Virus Type 1 Protease Inhibitors
1998
Class-Sparing Regimens for Initial Treatment of HIV-1 Infection
2008
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
1996
Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
2012
Primary drug resistance and transmission analysis of HIV‐1 in acute and recent drug‐naïve seroconverters in Singapore
2009
High-Risk Sexual Behavior in Adults With Genotypically Proven Antiretroviral-Resistant HIV Infection
2005
Impact of Antiretroviral Therapy and Changes in Virus Load on Human Immunodeficiency Virus (HIV)–Specific T Cell Responses in Primary HIV Infection
2003
A Once-Daily Lopinavir/Ritonavir-Based Regimen Is Noninferior to Twice-Daily Dosing and Results in Similar Safety and Tolerability in Antiretroviral-Naive Subjects Through 48 Weeks
2009
Antiretroviral Therapy for HIV Infection
1998
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model
2008 Standout
Viral Population Estimation Using Pyrosequencing
2008
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
1997 Standout
An Intracellular Trafficking Defect in Type I Cystinuria rBAT Mutants M467T and M467K
1997
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
1997 Standout
Immune Restoration With Antiretroviral Therapies
2000
Tuberculosis in Patients with Human Immunodeficiency Virus Infection
1999 Standout
Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine
2004
Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores
2007
Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2.
1996
Functional Impairment of CD8+ T Cells by Regulatory T Cells during Persistent Retroviral Infection
2004 StandoutNobel
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
2009
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
2009
Quinoline-based compounds as modulators of HIV transcription through NF-κB and Sp1 inhibition
2010
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
2006
A Prospective, Randomized Trial of Structured Treatment Interruption for Patients with Chronic HIV Type 1 Infection
2005
Restoration of Normal Interleukin‐2 Production by CD4+T Cells of Human Immunodeficiency Virus–Infected Patients after 9 Months of Highly Active Antiretroviral Therapy
1999
Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
1998 Standout
Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation
2010 Standout
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study
1999 Standout
The end of AIDS: HIV infection as a chronic disease
2013 Standout
Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir
2005
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385
2006
Molecular Methods and Platforms for Infectious Diseases Testing
2011
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
2009
Pharmacokinetics, Safety, and Efficacy of Tipranavir Boosted With Ritonavir Alone or in Combination With Other Boosted Protease Inhibitors as Part of Optimized Combination Antiretroviral Therapy in Highly Treatment-Experienced Patients (BI Study 1182.51)
2008
Tipranavir
2008
HIV Drug Resistance
2004
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
2008
MEC-2 regulates C. elegans DEG/ENaC channels needed for mechanosensation
2002 StandoutNatureNobel
Molecular Epidemiology Reveals Long‐Term Changes in HIV Type 1 Subtype B Transmission in Switzerland
2010
Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART
2001
Global epidemiology of HIV infection in men who have sex with men
2012 Standout
Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy
2000
Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey
2007
Preliminary Evidence for Partial Restoration of Immune Function in HIV Type 1 Infection with Potent Antiretroviral Therapies: Clues from the Fourth Conference on Retroviruses and Opportunistic Diseases
1997
Periodontal diseases
2005 Standout
Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug‐Resistant HIV‐1–Infected Patients: A Randomized Open‐Label Trial
2009
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial
2007
Proline-catalysed Mannich reactions of acetaldehyde
2008 StandoutNatureNobel
Immunological recovery and antiretroviral therapy in HIV-1 infection
2006
Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on Survival
2008
Convergent Mechanisms for Recognition of Divergent Cytokines by the Shared Signaling Receptor gp130
2003 StandoutNobel
The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States
2006
Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS
2005 StandoutNobel
Minority Quasispecies of Drug‐Resistant HIV‐1 That Lead to Early Therapy Failure in Treatment‐Naive and ‐Adherent Patients
2008
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
2006
Therapeutic dendritic-cell vaccine for simian AIDS
2002
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis
2007 Standout
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Synthetic therapeutic peptides: science and market
2009
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
2007
Equivalent Immunogenicity of the Highly Attenuated Poxvirus-Based ALVAC-SIV and NYVAC-SIV Vaccine Candidates in SIVmac251-Infected Macaques
2002
Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients
2008
Protein Sequence Editing of SKN-1A/Nrf1 by Peptide:N-Glycanase Controls Proteasome Gene Expression
2019 StandoutNobel
HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors
2002
Visual Demonstration of Hepatitis C Virus–Specific Memory Cd8+ T–Cell Expansion in Patients With Acute Hepatitis C
2001
Emergence of HIV-1 Drug Resistance in Previously Untreated Patients Initiating Combination Antiretroviral Treatment<subtitle>A Comparison of Different Regimen Types</subtitle>
2007
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection
2001
Copper-Mediated Coupling Reactions and Their Applications in Natural Products and Designed Biomolecules Synthesis
2008 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
2011 StandoutNobel
IL-7 Stimulates T Cell Renewal Without Increasing Viral Replication in Simian Immunodeficiency Virus-Infected Macaques
2003 StandoutNobel
Therapeutic drug monitoring of antiretrovirals for people with HIV
2009
Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection
2008
Characterization and structural analysis of HIV-1 integrase conservation.
2009
Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004
2008
Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment
2008
Sequence-Specific Detection of Femtomolar DNA via a Chronocoulometric DNA Sensor (CDS): Effects of Nanoparticle-Mediated Amplification and Nanoscale Control of DNA Assembly at Electrodes
2006
Aptamers Selected for Higher-Affinity Binding Are Not More Specific for the Target Ligand
2006 StandoutNobel
Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity
2005
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Quality Assurance Program for Clinical Measurement of Antiretrovirals: AIDS Clinical Trials Group Proficiency Testing Program for Pediatric and Adult Pharmacology Laboratories
2004
Status of Activation of Circulating Vaccine-Elicited CD8+ T Cells
2000
Antiretroviral Treatment of Adult HIV Infection
2014
Advances in the Chemistry of Tetrahydroquinolines
2011 Standout
Interleukin-7 and infection itself by human immunodeficiency virus 1 favor virus persistence in mature CD4+CD8−CD3+ thymocytes through sustained induction of Bcl-2
2001 StandoutNobel
Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection
2000
Transmission of drug-resistant HIV-1 in Europe remains limited to single classes
2008
Gold Nanoparticles in Chemical and Biological Sensing
2012 Standout
Vigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of Viremia
1997 StandoutScience
Maintenance of Large Numbers of Virus-Specific CD8+ T Cells in HIV-Infected Progressors and Long-Term Nonprogressors
2000
In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination
2004 StandoutNobel
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial
2006
HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function
2000
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
2015 Standout
Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors
2004 StandoutNobel
Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS
2005 StandoutNobel
The Long-Term Stability of the Human Gut Microbiota
2013 StandoutScience
Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID
2011
Medication adherence among HIV+ adults
2002
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
1997 StandoutScience
Information theory in molecular biology
2004
Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells
2001 StandoutNobel
Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression
1999
Comparative Studies on Retroviral Proteases: Substrate Specificity
2010
Works of Jonathan Schapiro being referenced
Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations
1999
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study
2000
Economic Evaluation of Drug Resistance Genotyping for the Adaptation of Treatment in HIV-Infected Patients in the VIRADAPT Study
2000
Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV‐infected patients experiencing prolonged virologic failure
2004
Localization of a gene causing cystinuria to chromosome 2p
1994
Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C
2004
Therapeutic Drug Monitoring
2003
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
2006
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide
2004
Antiretroviral Drug Resistance Testing in Adult HIV‐1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel
2008
The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients
1996
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors
2003
Changes in CD4 + and CD8 + T Cell Subsets in Response to Highly Active Antiretroviral Therapy in HIV Type 1-Infected Patients with Prior Protease Inhibitor Experience
1998
Update of the drug resistance mutations in HIV-1: Fall 2006.
2006
Update of the drug resistance mutations in HIV-1: 2007.
2007
Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir
2006
Update of the drug resistance mutations in HIV-1: 2004.
2004
Mutations in the SLC3A1 transporter gene in cystinuria.
1995
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.
2008
Drug Resistance Mutations in HIV-1.
2003
Update of the drug resistance mutations in HIV-1: Fall 2005.
2006
Human Immunodeficiency Virus Type 1 Protease Genotypes and In Vitro Protease Inhibitor Susceptibilities of Isolates from Individuals Who Were Switched to Other Protease Inhibitors after Long-Term Saquinavir Treatment
1998
The Influence of Protease Inhibitor Resistance Profiles on Selection of HIV Therapy in Treatment-Naive Patients
2004
Frequency of Class I HLA-Restricted Anti-HIV CD8+ T Cells in Individuals Receiving Highly Active Antiretroviral Therapy (HAART)
1999